This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Illumina (ILMN) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Illumina (ILMN) exhibits robust growth in the fourth quarter of fiscal 2019, fueled by strong performance of the sequencing consumable segment.
Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid
by Zacks Equity Research
We are upbeat that two of Thermo Fisher's (TMO) four business segments deliver strong year-over-year revenue growth in Q4.
AmerisourceBergen (ABC) Q1 Earnings Beat, Revenues Miss
by Zacks Equity Research
AmerisourceBergen's (ABC) Q1 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
Cerner (CERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to have aided Cerner's (CERN) Q4 earnings. However, contraction in gross margin is likely to have been a dampener.
McKesson (MCK) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) core U.S. Pharmaceutical and Specialty Solutions unit is expected to reflect in fiscal Q3 results.
Varian (VAR) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
Varian (VAR) gains from core Oncology segment in fiscal Q1.
Align Technology (ALGN) Earnings Beat in Q4, Margins Rise
by Zacks Equity Research
We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies during Q4.
Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?
by Zacks Equity Research
Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.
Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) fourth-quarter earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.
What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?
by Zacks Equity Research
Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.
Accuray (ARAY) Q2 Earnings Top Estimates, Gross Orders Fall
by Zacks Equity Research
Service revenues drive Accuray's (ARAY) Q2 results, gross margin expands.
PerkinElmer (PKI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PerkinElmer's (PKI) Q4 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher revenues, solid product portfolio and strong performance across six global business units are likely to have benefited Baxter's (BAX) Q4 earnings.
Here's Why You Should Add HealthEquity (HQY) to Portfolio Now
by Zacks Equity Research
Solid prospects in the HSA industry consistently drive HealthEquity (HQY).
DexCom (DXCM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $235.45 in the latest trading session, marking a +0.65% move from the prior day.
Hill-Rom's (HRC) Q1 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Sales in Hill-Rom's (HRC) Surgical Solutions suffer a massive setback, thanks to the divestiture of surgical consumables.
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
by Zacks Equity Research
Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?
by Zacks Equity Research
Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?
by Zacks Equity Research
Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.
What's in Store for AmerisourceBergen (ABC) in Q1 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) Q1 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.
Intuitive Surgical (ISRG) Q4 Earnings Top, Margins Expand
by Zacks Equity Research
Intuitive Surgical (ISRG) gains from solid international show in Q4.
NextGen (NXGN) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
NextGen (NXGN) gains from Recurring revenues in Q3, bookings down.
Best Thematic ETFs for 2020: Cloud, Internet of Things & More
by Neena Mishra
Find out more about cloud computing, Internet of Things, video games and infrastructure ETFs.
Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.